AstraZeneca's shares fell by 9% following the announcement that its experimental heart failure drug, tralokinumab, failed to meet its primary endpoint in a phase 3 clinical trial for patients with reduced ejection fraction. This setback marks a significant disappointment for the company, as tralokinumab was considered a key asset in its cardiovascular disease pipeline, which the company had been building up through recent acquisitions, including the $39 billion purchase of Alexion.
Analysts reacted to the news with concern, particularly given previous pipeline setbacks. Liberum analysts highlighted the trial failure as another blow after an earlier lung cancer drug setback, emphasizing the importance of drug development in sustaining growth. This news also comes after AstraZeneca faced a $100 million hit from
